Skip to main content
. 2022 Mar 18;10(3):e004316. doi: 10.1136/jitc-2021-004316

Figure 1.

Figure 1

PFS and OS by PD-L1 expression assessed by % TCs or CPS. (A) PFS with nivolumab plus ipilimumab vs sunitinib in patients with PD-L1 expression on <1% and ≥1% TCs. (B) PFS with nivolumab plus ipilimumab vs sunitinib in patients with PD-L1 CPS <1 and ≥1. (C) OS with nivolumab plus ipilimumab vs sunitinib in patients with PD-L1 expression on <1% and ≥1% TCs. (D) OS with nivolumab plus ipilimumab vs sunitinib in patients with PD-L1 CPS <1 and ≥1. CPS, combined positive score; IPI, ipilimumab; NIVO, nivolumab; NR, not reached; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; SUN, sunitinib; TC, tumor cell.